Print ISSN:-2581-5555

Online ISSN:-2456-9542

CODEN : IIJCDU


Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 1018

PDF Downloaded: 736


Diabetic nephropathy: Pathophysiology, Staging, Prevalence, and Management


Full Text PDF Share on Facebook Share on Twitter


Review Article

Author Details : Julia Anna Johnson, Sanjiv Karale*, Maria Elza Joseph, Jincy Abraham, Shamil Shahadan

Volume : 5, Issue : 2, Year : 2020

Article Page : 66-72

https://doi.org/10.18231/j.ijcaap.2020.015



Suggest article by email

Get Permission

Abstract

Diabetes mellitus (DM) has become a significant economic burden because of high healthcare costs for the treatment and its related complications. Chronic hyperglycemia, affect severely our organ systems mainly, cardiovascular, nervous, and renal system. These diabetic complications can progress into morbidity and mortality. Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) which affects 20–30% diabetic patients, characterized by sustained reduction in end glomerular filtration rate (GFR)and persistently high urinary albumin-to-creatinine ratio. Elevated glucose levels, high blood pressure long
duration of diabetes, obesity, and dyslipidemia can increase the progression of DN. The pathophysiology of DN is mainly due to result of interactions between metabolic and hemodynamic pathways, which are often disrupted in diabetes. Pharmacological approaches for DN mainly include regulation of BP, control of blood sugar level, use of hypolipidemic agents, quitting smoking, diet control, and use of vitamin D receptor agonists. Hence, strategies of treatment like BP control and dyslipidemia control etc. are required to decrease the burden of DN and prevent its progression to end stage renal disease (ESRD).

Keywords: Diabetes mellitus, Diabetic nephropathy, Hypertension, Dyslipidemia, Statins, End stage renal disease.



How to cite : Johnson J A, Karale S, Joseph M E, Abraham J, Shahadan S , Diabetic nephropathy: Pathophysiology, Staging, Prevalence, and Management. IP Int J Compr Adv Pharmacol 2020;5(2):66-72


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.